| 1. |
- Tønnesen, Hanne, et al.
(författare)
-
Smoking cessation intervention in emergency neurology - introduction of a new practice
- 2012
-
Ingår i: Clinical Health Promotion. - 2226-5864. ; 2:2, s. 64-69
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction Emergency neurological patients are rarely given opportunities for smoking and alcohol intervention. How-ever, both are relevant in the acute phase as well as in future rehabilitation.Objectives The aim of this study was primarily to illustrate the implementation of motivational counselling in an acute neurological department and also to predict factors influencing this motivation.MethodsDuring a four-month period, 100 smoking emergency patients, including 18 patients with hazardously drinking patterns, were admitted with acute neurological illness, offered behavioural counselling before discharge, participated in a six week hospital-based smoking cessation or alcohol intervention programme, and followed-up after six months.ResultsOf the 100 patients studied, 87 accepted counselling regarding smoking and 16 patients received counselling for both smoking and alcohol. The younger patients had the highest level of motivation. Sixty (69%) patients were con- tactable at follow-up; of these, 18 patients had continuously quit smoking for six months and the other 15 patients had ceased or reduced their smoking habits. The followed-up group included only 6 (38%) with hazardous drinking patterns. ConclusionThe majority of smokers admitted due to emergency neurological illness accepted an offer for motivational counselling followed by a six week smoking cessation programme. The results indicated that this counselling led a signifi-cant proportion of the patients to cease or reduce their smoking habits.
|
|
| 2. |
- Backer, Vibeke, et al.
(författare)
-
Clinical characteristics of the BREATHE cohort–a real-life study on patients with asthma and COPD
- 2020
-
Ingår i: European clinical respiratory journal. - : Informa UK Limited. - 2001-8525. ; 7:1
-
Tidskriftsartikel (refereegranskat)abstract
- Background: The BREATHE study is a cross-sectional study of real-life patients with asthma and/or COPD in Denmark and Sweden aiming to increase the knowledge across severities and combinations of obstructive airway disease. Design: Patients with suspicion of asthma and/or COPD and healthy controls were invited to participate in the study and had a standard evaluation performed consisting of questionnaires, physical examination, FeNO and lung function, mannitol provocation test, allergy test, and collection of sputum and blood samples. A subgroup of patients and healthy controls had a bronchoscopy performed with a collection of airway samples. Results: The study population consisted of 1403 patients with obstructive airway disease (859 with asthma, 271 with COPD, 126 with concurrent asthma and COPD, 147 with other), and 89 healthy controls (smokers and non-smokers). Of patients with asthma, 54% had moderate-to-severe disease and 46% had mild disease. In patients with COPD, 82% had groups A and B, whereas 18% had groups C and D classified disease. Patients with asthma more frequently had childhood asthma, atopic dermatitis, and allergic rhinitis, compared to patients with COPD, asthma + COPD and Other, whereas FeNO levels were higher in patients with asthma and asthma + COPD compared to COPD and Other (18 ppb and 16 ppb vs 12.5 ppb and 14 ppb, p < 0.001). Patients with asthma, asthma + COPD and Other had higher sputum eosinophilia (1.5%, 1.5%, 1.2% vs 0.75%, respectively, p < 0.001) but lower sputum neutrophilia (39.3, 43.5%, 40.8% vs 66.8%, p < 0.001) compared to patients with COPD. Conclusions: The BREATHE study provides a unique database and biobank with clinical information and samples from 1403 real-life patients with asthma, COPD, and overlap representing different severities of the diseases. This research platform is highly relevant for disease phenotype- and biomarker studies aiming to describe a broad spectrum of obstructive airway diseases.
|
|
| 3. |
- Backer, Vibeke, et al.
(författare)
-
Får man astma af at dyrke topidræt?
- 2006
-
Ingår i: Ugeskrift for Læger. - 0041-5782. ; 168:51, s. 4532-4532
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Abstract in Danish I de industrialiserede lande har 7-10% af den voksne befolkning astma, og tallet har de seneste årtier været stigende [1]. Lægediagnosticeret astma i Danmark er øget fra 4 til 7-10%, og allergisk rinitis eller kronisk ikkeallergisk rinitis er øget fra 10% til 20-25% over en 20-årig periode [2]. Astma er den hyppigste kroniske sygdom hos unge og unge voksne, og en høj forekomst af astma i befolkningen må naturligt følges af en høj forekomst af astma hos idrætsudøvere, men astma er ikke noget, som idrætsudøvere generelt synes at have forud for deres debut som eliteidrætsudøvere.
|
|
| 4. |
- Conti, Diego M., et al.
(författare)
-
A EUFOREA comment on a lost comorbidity of asthma
- 2023
-
Ingår i: Allergy, Asthma and Clinical Immunology. - 1710-1484. ; 19:1
-
Tidskriftsartikel (refereegranskat)abstract
- “Epidemiology of comorbidities and their association with asthma control” (Tomisa, G., Horváth, A., Sánta, B. et al. Epidemiology of comorbidities and their association with asthma control. Allergy Asthma Clin Immunol 17, 95 (2021). https://doi.org/10.1186/s13223-021-00598-3) is an interesting paper reflecting data collection from more than 12,000 asthmatic patients in Hungary regarding their condition and associated comorbidities. We found it valuable that the paper provides an overview of asthma comorbidities not usually considered in similar reports. Nevertheless, we believe that chronic rhinosinusitis (CRS) with or without nasal polyps (CRSwNP or CRSsNP) should have been listed due to its high incidence and prevalence, its association with asthma which is also endorsed in both GINA and EPOS, as well as in several peer-reviewed scientific papers, and to reflect the role of this comorbidity in poor control and a most severe presentation of asthma for the patient. Consequently, several targeted therapies (especially monoclonal antibodies) used for several years in severe forms of asthma are now indicated also for the effective treatment of nasal polyps.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Gudbjartsson, Daniel F., et al.
(författare)
-
Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction
- 2009
-
Ingår i: Nature Genetics. - : Springer Science and Business Media LLC. - 1061-4036 .- 1546-1718. ; 41:3, s. 342-347
-
Tidskriftsartikel (refereegranskat)abstract
- Eosinophils are pleiotropic multifunctional leukocytes involved in initiation and propagation of inflammatory responses and thus have important roles in the pathogenesis of inflammatory diseases. Here we describe a genome-wide association scan for sequence variants affecting eosinophil counts in blood of 9,392 Icelanders. The most significant SNPs were studied further in 12,118 Europeans and 5,212 East Asians. SNPs at 2q12 (rs1420101), 2q13 (rs12619285), 3q21 (rs4857855), 5q31 (rs4143832) and 12q24 (rs3184504) reached genome-wide significance (P = 5.3 x 10(-14), 5.4 x 10(-10), 8.6 x 10(-17), 1.2 x 10(-10) and 6.5 x 10(-19), respectively). A SNP at IL1RL1 associated with asthma (P = 5.5 x 10(-12)) in a collection of ten different populations (7,996 cases and 44,890 controls). SNPs at WDR36, IL33 and MYB that showed suggestive association with eosinophil counts were also associated with atopic asthma (P = 4.2 x 10(-6), 2.2 x 10(-5) and 2.4 x 10(-4), respectively). We also found that a nonsynonymous SNP at 12q24, in SH2B3, associated significantly (P = 8.6 x 10(-8)) with myocardial infarction in six different populations (6,650 cases and 40,621 controls).
|
|
| 8. |
- Heaney, Liam G., et al.
(författare)
-
Eosinophilic and Noneosinophilic Asthma : An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort
- 2021
-
Ingår i: Chest. - : Elsevier BV. - 0012-3692. ; 160:3, s. 814-830
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Phenotypic characteristics of patients with eosinophilic and noneosinophilic asthma are not well characterized in global, real-life severe asthma cohorts. Research Question: What is the prevalence of eosinophilic and noneosinophilic phenotypes in the population with severe asthma, and can these phenotypes be differentiated by clinical and biomarker variables? Study Design and Methods: This was an historical registry study. Adult patients with severe asthma and available blood eosinophil count (BEC) from 11 countries enrolled in the International Severe Asthma Registry (January 1, 2015-September 30, 2019) were categorized according to likelihood of eosinophilic phenotype using a predefined gradient eosinophilic algorithm based on highest BEC, long-term oral corticosteroid use, elevated fractional exhaled nitric oxide, nasal polyps, and adult-onset asthma. Demographic and clinical characteristics were defined at baseline (ie, 1 year before or closest to date of BEC). Results: One thousand seven hundred sixteen patients with prospective data were included; 83.8% were identified as most likely (grade 3), 8.3% were identified as likely (grade 2), and 6.3% identified as least likely (grade 1) to have an eosinophilic phenotype, and 1.6% of patients showed a noneosinophilic phenotype (grade 0). Eosinophilic phenotype patients (ie, grades 2 or 3) showed later asthma onset (29.1 years vs 6.7 years; P < .001) and worse lung function (postbronchodilator % predicted FEV1, 76.1% vs 89.3%; P = .027) than those with a noneosinophilic phenotype. Patients with noneosinophilic phenotypes were more likely to be women (81.5% vs 62.9%; P = .047), to have eczema (20.8% vs 8.5%; P = .003), and to use anti-IgE (32.1% vs 13.4%; P = .004) and leukotriene receptor antagonists (50.0% vs 28.0%; P = .011) add-on therapy. Interpretation: According to this multicomponent, consensus-driven, and evidence-based eosinophil gradient algorithm (using variables readily accessible in real life), the severe asthma eosinophilic phenotype was more prevalent than previously identified and was phenotypically distinct. This pragmatic gradient algorithm uses variables readily accessible in primary and specialist care, addressing inherent issues of phenotype heterogeneity and phenotype instability. Identification of treatable traits across phenotypes should improve therapeutic precision.
|
|
| 9. |
- Hostrup, Morten, et al.
(författare)
-
Mechanisms underlying enhancements in muscle force and power output during maximal cycle ergometer exercise induced by chronic beta(2)-adrenergic stimulation in men
- 2015
-
Ingår i: Journal of applied physiology. - : American Physiological Society. - 8750-7587 .- 1522-1601. ; 119:5, s. 475-486
-
Tidskriftsartikel (refereegranskat)abstract
- The study was a randomized placebo-controlled trial investigating mechanisms by which chronic beta(2)-adrenergic stimulation enhances muscle force and power output during maximal cycle ergometer exercise in young men. Eighteen trained men were assigned to an experimental group [oral terbutaline 5 mg/30 kg body weight (bw) twice daily (TER); n = 9] or a control group [placebo (PLA); n = 9] for a 4-wk intervention. No changes were observed with the intervention in PLA. Isometric muscle force of the quadriceps increased (P <= 0.01) by 97 +/- 29 N (means +/- SE) with the intervention in TER compared with PLA. Peak and mean power output during 30 s of maximal cycling increased (P <= 0.01) by 32 +/- 8 and 25 +/- 9 W, respectively, with the intervention in TER compared with PLA. Maximal oxygen consumption ((V) over dotO(2)max) and time to fatigue during incremental cycling did not change with the intervention. Lean body mass increased by 1.95 +/- 0.8 kg (P <= 0.05) with the intervention in TER compared with PLA. Change in single fiber cross-sectional area of myosin heavy chain (MHC) I (1,205 +/- 558 mu m(2); P <= 0.01) and MHC II fibers (1,277 +/- 595 mu m(2); P <= 0.05) of the vastus lateralis muscle was higher for TER than PLA with the intervention, whereas no changes were observed in MHC isoform distribution. Expression of muscle proteins involved in growth, ion handling, lactate production, and clearance increased (P <= 0.05) with the intervention in TER compared with PLA, with no change in oxidative enzymes. Our observations suggest that muscle hypertrophy is the primary mechanism underlying enhancements in muscle force and peak power during maximal cycling induced by chronic beta(2-)adrenergic stimulation in humans.
|
|
| 10. |
- Kalsen, Anders, et al.
(författare)
-
Inhaled Beta2-agonist Increases Power Output and Glycolysis during Sprinting in Men.
- 2016
-
Ingår i: Medicine & Science in Sports & Exercise. - 0195-9131 .- 1530-0315. ; 48:1, s. 39-48
-
Tidskriftsartikel (refereegranskat)abstract
- PURPOSE: The aim of the present study was to investigate the effect of the beta2-agonist terbutaline (TER) on power output and muscle metabolism during maximal sprint cycling.METHODS: In a randomized double-blind crossover design, nine moderately trained men (VO2max: 4.6±0.2 L[BULLET OPERATOR]min) conducted a 10-s cycle sprint after inhalation of either 15 mg TER or placebo (PLA). A muscle biopsy was collected before and <10 s after the sprint, and analyzed for metabolites.RESULTS: Mean and peak power during the sprint were 8.3±1.1 and 7.8±2.5 % higher (P<0.05) in TER than in PLA, respectively. Moreover, net rate of glycogenolysis (6.5±0.8 vs. 3.1±0.7 mmol glucosyl units kg dw s) and glycolysis (2.4±0.2 vs. 1.6±0.2 mmol glucosyl units kg dw s) were higher (P<0.05) in TER than in PLA. After the sprint, ATP was reduced in PLA (P<0.05), but not in TER. During the sprint, there was no difference in breakdown of phosphocreatine (PCr) between treatments. Estimated anaerobic ATP utilization was 9.2 ±4.0 % higher (P<0.05) in TER than in PLA. After the sprint, ATP was lowered (P <0.05) by 25.7±7.3 % in type II fibers in PLA with no reduction in TER. Before the sprint, PCr was 24.5±7.2 % lower (P <0.05) in type II fibers in TER than in PLA. In PLA, breakdown of PCr was 50.2±24.8 % higher (P <0.05) in type II than in type I fibers with no difference in TER.CONCLUSION: The present study shows that a terbutaline-induced increase in power output is associated with increased rates of glycogenolysis and glycolysis in skeletal muscles. Furthermore, as terbutaline counteracted a reduction in ATP in type II fibers, terbutaline may postpone fatigue development in these fibers.
|
|
